PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who...
Latest News
PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD™), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM) demonstrated a statistically significant improvement in minimal residual disease (MRD) negativity...
Cambridge, Mass. – By analyzing millions of small genetic differences across a person’s genome, researchers can calculate a polygenic risk score to estimate someone’s lifetime odds of developing a certain disease. Over the past decade, scientists have developed these risk scores for dozens of diseases, including heart disease, kidney disease,...
Altering a protein linked to Rett syndrome so that it cannot bind to a particular type of DNA tag results in traits reminiscent of the syndrome, according to a new study in mice. The findings could help explain the syndrome’s delayed onset in people: Because the tag does not arise until after...
CAMBRIDGE & LONDON, England — Broken String Biosciences, a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has entered a research collaboration with the Francis Crick Institute, a world-leading biomedical discovery institute dedicated to understanding the biology...
Alfred Santiago the third needs your help. The 2-year-old was born with a rare congenital disorder where a part of his brain is shrinking over time. His father, Alfred Santiago Jr., who works and lives part-time in the Bronx, has found a California doctor who will perform a stem-cell surgery...
BROOKLYN, Mich. – Full of life and full of love. That’s who four year-old Jaxon Meschke is. “All my friends! I love mom. I love dad and baby brother,” said four-year old Jaxon. But it’s his perseverance that stands out to his parents Brian and Chelsea Meschke most. “He really...
EATONS HILL — An Eatons Hill family knows the daily battles of managing life with cystic fibrosis. Alison and Ben Perkin are the proud parents of four children, two of whom have cystic fibrosis (CF), the most common incurable genetic condition that substantially shortens life expectancy. Mrs Perkin said her...
SAN CARLOS, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The...
CAMBRIDGE, Mass. & BEIJING – BeiGene (NASDAQ: BGNE; HKEX: 06160) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing BRUKINSA® (zanubrutinib) against ibrutinib in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). BRUKINSA met the primary endpoint of the trial, demonstrating...